564 related articles for article (PubMed ID: 33881741)
1. IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.
Roh YS; Choi J; Sutaria N; Belzberg M; Kwatra MM; Kwatra SG
Drugs; 2021 Jun; 81(8):895-905. PubMed ID: 33881741
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulating Agents as Antipruritics.
Erickson S; Nahmias Z; Rosman IS; Kim BS
Dermatol Clin; 2018 Jul; 36(3):325-334. PubMed ID: 29929604
[TBL] [Abstract][Full Text] [Related]
3. IL-31: a new link between T cells and pruritus in atopic skin inflammation.
Sonkoly E; Muller A; Lauerma AI; Pivarcsi A; Soto H; Kemeny L; Alenius H; Dieu-Nosjean MC; Meller S; Rieker J; Steinhoff M; Hoffmann TK; Ruzicka T; Zlotnik A; Homey B
J Allergy Clin Immunol; 2006 Feb; 117(2):411-7. PubMed ID: 16461142
[TBL] [Abstract][Full Text] [Related]
4. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
5. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
6. Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Mollanazar NK; Smith PK; Yosipovitch G
Clin Rev Allergy Immunol; 2016 Dec; 51(3):263-292. PubMed ID: 25931325
[TBL] [Abstract][Full Text] [Related]
7. Chronic itch in African Americans: an unmet need.
Ingrasci G; El-Kashlan N; Alexis A; Yosipovitch G
Arch Dermatol Res; 2022 Jul; 314(5):405-415. PubMed ID: 34129098
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for the treatment of pruritus.
Ständer S; Weisshaar E; Raap U
Expert Opin Emerg Drugs; 2015 Sep; 20(3):515-21. PubMed ID: 26027744
[TBL] [Abstract][Full Text] [Related]
9. A critical evaluation of nemolizumab for prurigo nodularis.
Brooks SG; Yosipovitch G
Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
[TBL] [Abstract][Full Text] [Related]
10. Clinical aspects and management of chronic itch.
Zeidler C; Raap U; Witte F; Ständer S
J Allergy Clin Immunol; 2023 Jul; 152(1):1-10. PubMed ID: 37178730
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-31 and Pruritic Skin.
Furue M; Furue M
J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33924978
[TBL] [Abstract][Full Text] [Related]
12. Management of itch in atopic dermatitis.
Hong J; Buddenkotte J; Berger TG; Steinhoff M
Semin Cutan Med Surg; 2011 Jun; 30(2):71-86. PubMed ID: 21767767
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 31 and skin diseases: A systematic review.
Gangemi S; Quartuccio S; Casciaro M; Trapani G; Minciullo PL; Imbalzano E
Allergy Asthma Proc; 2017 Nov; 38(6):401-408. PubMed ID: 29046191
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.
Furue M; Yamamura K; Kido-Nakahara M; Nakahara T; Fukui Y
Allergy; 2018 Jan; 73(1):29-36. PubMed ID: 28670717
[TBL] [Abstract][Full Text] [Related]
15. New and emerging treatments for inflammatory itch.
Erickson S; Heul AV; Kim BS
Ann Allergy Asthma Immunol; 2021 Jan; 126(1):13-20. PubMed ID: 32497711
[TBL] [Abstract][Full Text] [Related]
16. Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.
Inan S; Torres-Huerta A; Jensen LE; Dun NJ; Cowan A
Eur J Pharmacol; 2019 Dec; 864():172702. PubMed ID: 31568781
[TBL] [Abstract][Full Text] [Related]
17. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
Liao V; Cornman HL; Ma E; Kwatra SG
Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
[TBL] [Abstract][Full Text] [Related]
18. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis.
Takaoka A; Arai I; Sugimoto M; Honma Y; Futaki N; Nakamura A; Nakaike S
Exp Dermatol; 2006 Mar; 15(3):161-7. PubMed ID: 16480423
[TBL] [Abstract][Full Text] [Related]
19. New mechanism underlying IL-31-induced atopic dermatitis.
Meng J; Moriyama M; Feld M; Buddenkotte J; Buhl T; Szöllösi A; Zhang J; Miller P; Ghetti A; Fischer M; Reeh PW; Shan C; Wang J; Steinhoff M
J Allergy Clin Immunol; 2018 May; 141(5):1677-1689.e8. PubMed ID: 29427643
[TBL] [Abstract][Full Text] [Related]
20. Atopic dermatitis in children: management of pruritus.
Blume-Peytavi U; Metz M
J Eur Acad Dermatol Venereol; 2012 Nov; 26 Suppl 6():2-8. PubMed ID: 23067431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
